Sutton, T A
Sohrabi, H R
Rainey-Smith, S R
Bird, S M
Weinborn, M
Martins, R N
Article History
Received: 16 December 2014
Revised: 27 January 2015
Accepted: 23 February 2015
First Online: 31 March 2015
Competing interests
: RNM is the founder and owns stocks of Alzhyme. HRS has previously received payments from Wyeth and Pfizer, and is currently receiving remuneration for ongoing work as part of the Takeda Pharmaceutical TOMMORROW Study (TOMM40 Trial). The remaining authors declare no conflict of interest.